2022
Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomes
2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsAbrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.Peer-Reviewed Original ResearchProstate cancer-specific survivalU.S. Preventive Services Task ForceSurvival disparitiesUninsured patientsSocioeconomic quintileProstate cancerInsurance statusMarital statusWorse prostate cancer-specific survivalProstate cancer screening recommendationsCox proportional hazards modelDiagnostic time periodsCancer-specific survivalCancer screening recommendationsProportional hazards modelProstate-specific antigenScreening recommendationsSurvival outcomesInsured patientsWorse outcomesHazards modelPatientsBetter outcomesMedian household incomeUninsured individuals
2019
A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.Peer-Reviewed Original ResearchNon-muscle invasive BCMuscle-invasive BCIndependent prognostic biomarkerInvasive BCPrognostic biomarkerProlonged recurrence-free survivalCancer-specific survivalCancer-specific deathRecurrence-free survivalTissues of patientsBC tissue samplesExpression of mRNAVital clinical significanceMIBC patientsBC prognosisPoor prognosisBladder cancerClinical significanceCancer tumorigenesisUseful markerLow expressionPatientsNovel tumorHigh expressionTissue samples
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2015
Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma
Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal Of Urology 2015, 194: 1441-1448. PMID: 25796113, DOI: 10.1016/j.juro.2015.03.078.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternCarcinoma, Renal CellCell Line, TumorDisease ProgressionFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisReal-Time Polymerase Chain ReactionReceptors, AndrogenRetrospective StudiesRNA, NeoplasmTime FactorsYoung AdultConceptsRenal cell carcinomaAndrogen receptor mRNA expressionReceptor mRNA expression levelsCancer-specific survivalCell carcinomaCell carcinoma cell linesReceptor mRNA expressionHuman renal cell carcinoma cell linesRenal cell carcinoma cell linesAndrogen receptorMRNA expression levelsSpecific survivalCarcinoma cell linesMultivariate Cox regression analysisLocalized Renal Cell CarcinomaMRNA expressionT2 renal cell carcinomaCell linesPathological stage T1Androgen receptor expressionCox regression analysisKaplan-Meier estimatesReceptor-positive cell linesChain reactionPositive renal cell carcinomas
2014
Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2
Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersCarrier ProteinsEndopeptidasesFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessNeoplasm StagingPlatelet Glycoprotein GPIb-IX ComplexPredictive Value of TestsRegression AnalysisRisk FactorsROC CurveUbiquitin ThiolesteraseUrinary Bladder NeoplasmsConceptsCancer-specific survivalCancer-specific deathBladder cancer patientsHigh expression groupExpression of USP18MIBC patientsCancer patientsExpression groupMuscle-invasive bladder cancer patientsCancer-specific survival ratesInvasive bladder cancer patientsMuscle-invasive bladder cancerLonger cancer-specific survivalMultivariate Cox regression analysisCox regression analysisInvasive bladder cancerSignificant risk factorsReliable prognostic markersMRNA expression levelsSurvival-related genesOverall survivalValidation cohortOriginal cohortLonger survivalPredicting Survival
2013
Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer
Shim U, Lee I, Kang H, Kim J, Kim W, Kim I, Ryu K, Choi Y, Moon S, Kim Y, Yun S, Lee S, Kim W. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Investigative And Clinical Urology 2013, 54: 631-637. PMID: 24044099, PMCID: PMC3773595, DOI: 10.4111/kju.2013.54.9.631.Peer-Reviewed Original ResearchBladder cancerDBC1 expressionExpression of DBC1Prognostic valuePrognostic markerNon-muscle invasive bladder cancerMultivariate Cox regression analysisMultivariate Cox regression modelCancer-specific survivalCox regression analysisKaplan-Meier analysisPredictors of progressionCox regression modelKaplan-Meier estimatesUseful prognostic markerAggressive tumor characteristicsNormal bladder mucosaPolymerase chain reaction analysisTumor characteristicsPoor prognosisTumor recurrenceReal-time polymerase chain reaction analysisBladder mucosaClinicopathologic parametersNMIBCCancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis
Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis. European Urology 2013, 65: 693-700. PMID: 23759328, PMCID: PMC3825778, DOI: 10.1016/j.eururo.2013.05.023.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalCancer-specific survivalPrimary radical prostatectomyRadical prostatectomyRT groupRadiation therapyProstate cancerIntermediate-high riskRisk of PCSMCancer-specific mortalityEnd Results-MedicarePrimary radiation therapyPropensity-matched cohortLow-risk patientsPrimary treatment modalityLocalized prostate cancerProstate cancer patientsDevelopment of metastasesOnset of metastasisResidual confoundersHazard ratioMetastatic diseaseRisk patientsClinical courseSurveillance Epidemiology
2010
Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping
Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorDNA GlycosylasesFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMusclesNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPeptide Nucleic AcidsPolymerase Chain ReactionPolymorphism, GeneticPrognosisProportional Hazards ModelsUrinary Bladder NeoplasmsConceptsMuscle-invasive bladder cancerReal-time PCR clampingInvasive bladder cancerBladder cancerHOGG1 genotypeHOGG1 codon 326 genotypesMultivariate Cox regression analysisHOGG1 codon 326Cancer-specific survivalCox regression analysisPrognostic genetic markersPCR clampingSpecific survivalSurvival benefitClinicopathologic characteristicsBC patientsPrognostic indicatorTumor gradePrognostic markerClinical dataProtective effectCancerPatientsDNA damage repair mechanismsCodon 326